Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-07-12
2011-07-12
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021900, C514S021910
Reexamination Certificate
active
07977315
ABSTRACT:
Conjugated nitro alkene compounds hamper or prevent proliferation of cancer cells in cell culture and in cancer patients, which can result in a decrease in tumor size and/or disappearance of the cancer. The compounds may act by interference with cancer cell biochemistry, in which isoprenoid groups such as farnesyl and geranylgeranyl become bonded to various oncogenic proteins such as Ras, RhoA, RhoB, or some other growth-related cellular protein(s).
REFERENCES:
patent: 5595756 (1997-01-01), Balley et al.
patent: 6166082 (2000-12-01), Kluender et al.
patent: 7312191 (2007-12-01), Rose et al.
patent: 9301824 (1993-02-01), None
K. Okolotowicz et al. Archiv der Pharmazie (2001) 334(6) , pp. 194-202.
Schlitzer, M. et al., “Design, Synthesis and Early Structure-Activity Relationship of Farnesyltransferase Inhibitors Which Mimic Both the Peptidic and the Prenylic Substrate,” Bioorganic & Medicinal Chemistry 8 (2000) 2000 Elsevier Science Lts., pp. 1991-2006.
Schlitzer, M. et al., “Non-Peptidic, Non-Prenylic Bisubstrate Farnesyltransferase Inhibitors. Part 3: Structural Requirements of the Central Moiety for Farnesyltransferase Inhibitory Activity,” Biorganic & Meicinal Chemistry 8 (2000) 200 Elsevier Science Ltd., pp. 2399-2406.
Gura, T., “Systems for Identifying New Drugs are Often Faulty,” Science (1997), vol. 278, pp. 1041-1042.
Montagnier et al., Activites Cytotoxique Et Antitumorale Des Beta-Nitrostyrenes, Chimie Therapeutique, Editions Dimeo, Arcueil, Fr, vol. 6, No. 3, 1971, pp. 186-191.
Okolotowicz et al, “Inactivation of Protein Farnesyltransferase by Active-Site-Targeted Dicarbonyl Compounds,” Arch. Pharm. Med. Chem.(2001), vol. 334, pp. 194-202.
Bergo M.O., et al, “On the Physiological Importance of Endoproteolysis of CAAX Proteins: Heart-Specific RCEI Knockout Mice Develop a Lethal Cardiomyopathy,” J Biol Chem. Feb. 6, 2004; 279(6):4729-36. Epub Nov. 18, 2003.
http://en.wikipedia.org/wiki/In—vivo, 1 page. retrieved Aug. 27, 2006.
Organic Chemistry, 5th Ed. Morris & Boyd, p. 1205, 1 page. (1987).
Kabalka and Varma, Organic Preparations and Procedures International 1987, 19, 283-328.
The Merck Index Named Reactions, 182. Henry Reaction, 1 page. retrieved Jul. 17, 2003.
Nasr, et al., Advances in Pharmacology and Chemotherapy 1984, 20, 123-190.
Cassels, et al., Anales de la Asociacion Quimica Argentina 1982, 70, 283-8.
Yuen and Cheng, J. Med. Chem. 1969, 12, 157-161.
Alston, et al., Bioorganic Chemistry 1985, 13, 375-403.
Alston, et al., Acc. Chem. Res. 1983, 16, 418-424.
Fujii, Masayuki, “A Highly Chemoselective Reduction of Conjugated Nitro Olefins with Hantzsch Ester in the Presence of Silica Gel”, Bulletin of the Chemical Society of Japan,vol. 61(11), pp. 4029-4035 (1988).
Knight, John et al., “A New Acylative Cycoaddition Reaction”, Journal of the Chemical Society, Perkin Trans. I: Organic and Bio-Organic Chemistly (1972-1999), pp. 979-984 (1989).
Knight, John et al., “A New Acylative Cycloaddition Reaction”, Journal of the Chemical Society, Chemical Communications, pp. 189-190 (1987).
Knochel, Paul, et al., “Dehydration of Nitroaldols with Dicyclohexylcarbodiimide: Preparation of Nitroolefins under Mild Conditions” Synthesis, pp. 1017-1018 (1982).
Bezbarua, Maitreyee S., et al., “A Facile Procedure for the Conversion of Nitroolefins to Carbonyl Compounds using the Al-NiCl2*6H20-THF System”, Chemistry Letters, pp. 325-326 (1999).
Saikia, Anil K., et al., “The Zinc-Trifluoroacetic Acid Reaction in Organic Solvents: A Facile Procedure for the Conversion of Nitroolefins into Carbonyl Compounds under Mild Conditions”, Journal of Chemical Research, Synopses, pp. 124-125 (1996).
Saikia, Anil K., et al., “An Improved Synethsis of Conjugated Nitroolefins”, Synthesis, pp. 685-686 (1994).
International Search Report mailed Jan. 4, 2005 in counterpart PCT Application No. PCT/US2004/019110.
Hartman Rosemarie F.
Houtchens Jason
Okolotowicz Karl J.
Rose Seth D.
Arizona Biomedical Research Commission
Banner & Witcoff , Ltd.
Kosar Andrew D
LandOfFree
Conjugated nitro alkene anticancer agents based on... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugated nitro alkene anticancer agents based on..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugated nitro alkene anticancer agents based on... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2708747